SKYE
Skye Bioscience, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$28.10M
P/E Ratio
—
EPS
$-1.45
Beta
3.02
52W High
$5.75
52W Low
$0.57
50-Day MA
$0.81
200-Day MA
$1.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-58.36M |
| Operating Margin | 0.00% |
| Return on Equity | -168.00% |
| Return on Assets | -87.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.26 |
| Price-to-Book | 3.12 |
| Price-to-Sales (TTM) | 117.90 |
| EV/Revenue | 220.74 |
| EV/EBITDA | -2.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $35.14M |
| Float | $22.96M |
| % Insiders | 1.17% |
| % Institutions | 46.00% |
Historical Volatility
HV 10-Day
71.94%
HV 20-Day
96.16%
HV 30-Day
89.89%
HV 60-Day
86.49%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($7.71 target)
2
Strong Buy4
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026